| Drug Name: | Adenosine (58-61-7) |
|---|---|
| PubChem ID: | 60961 |
| SMILES: | C1=NC2=C(C(=N1)N)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O |
| InchiKey: | OIRDTQYFTABQOQ-KQYNXXCUSA-N |
| Therapeutic Category: | Analgesics, Anti-Arrhythmia Agents, Cardiovascular Agents, Central Nervous System Agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Purinergic Agents, Purinergic P1 Receptor Agonists, Sensory System Agents, Vasodilator Agents |
| Molecular Weight (dalton) | : | 267.245 |
| LogP | : | -1.98 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 9 |
| Hydrogen Bond Donor Count | : | 4 |
| Total Polar Surface Area | : | 139.54 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Dipyridamole (58-32-2) | Bradycardia | Antagonistic | Not fully understood. Part of the explanation is that dipyridamole increases plasma levels of endogenous adenosine by inhibiting its uptake into cells | Intravenous adenosine in the treatment of supraventricular tachycardia: a dose-ranging study and interaction with dipyridamole |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Ada Immunodeficiency (Scid) | Adenosine deaminase (P00813) | Both intracellular toxicity and signaling by extracellular adenosine may contribute to pathogenesis of ADA immunodeficiency (SCID) [ ADR Type 5 ] | The extracellular versus intracellular mechanisms of inhibition of TCR-triggered activation in thymocytes by adenosine under conditions of inhibited adenosine deaminase |
| Apoptosis | Protein tyrosine phosphatase (Q05209) | PTPase(s) plays an integral role in the induction of EC apoptosis upon exposure to homocysteine and/or adenosine@ possibly by the attenuation of p38alpha activity [ ADR Type 2 ] | Adenosine induces endothelial apoptosis by activating protein tyrosine phosphatase: a possible role of p38alpha |
| Tactile Allodynia | Mitogen-activated protein kinase 11 (Q15759) | Tactile allodynia under the chronic pain state requires an activation of the P2X(4) ionotropic ATP receptor and p38 mitogen-activated protein kinase (MAPK) in spinal cord microglia. [ ADR Type 1 2 ] | ATP- and adenosine-mediated signaling in the central nervous system: chronic pain and microglia: involvement of the ATP receptor P2X4 |
| Tactile Allodynia | P2X(4) ionotropic ATP receptor (P00040) | Tactile allodynia under the chronic pain state requires an activation of the P2X(4) ionotropic ATP receptor and p38 mitogen-activated protein kinase (MAPK) in spinal cord microglia. [ ADR Type 1 2 ] | ATP- and adenosine-mediated signaling in the central nervous system: chronic pain and microglia: involvement of the ATP receptor P2X4 |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category